AstraZeneca and Merck enter $8.5bn cancer therapy collaboration

AstraZeneca has entered into an oncology collaboration with Merck, under which the companies will co-develop AstraZeneca’s Lynparza (olaparib).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment

30 July 2020 Biopharmaceutical company AstraZeneca has struck a deal with Japanese pharmaceutical company Daiichi Sankyo to jointly develop and market a new medicine to treat lung, breast and other cancers.

Americas

Italian research organisation extends collaboration with Merck & Co

5 September 2018 Italy-based research organisation IRBM has signed a new agreement with Merck & Co in the peptides therapeutics area, extending the parties’ long-standing collaboration.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

AstraZeneca and Merck enter $8.5bn cancer therapy collaboration

More on this story

Editor's picks

Editor's picks

More features